259 related articles for article (PubMed ID: 18575763)
1. CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia.
Mainou-Fowler T; Porteous A; Nicolle A; Proctor SJ; Anderson JJ; Summerfield G
Int J Oncol; 2008 Jul; 33(1):169-74. PubMed ID: 18575763
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia.
Ibrahim S; Jilani I; O'Brien S; Rogers A; Manshouri T; Giles F; Faderl S; Thomas D; Kantarjian H; Keating M; Albitar M
Cancer; 2003 Apr; 97(8):1914-9. PubMed ID: 12673718
[TBL] [Abstract][Full Text] [Related]
3. T-cell CD38 expression in B-chronic lymphocytic leukaemia.
Abousamra NK; El-Din MS; Azmy E
Hematol Oncol; 2009 Jun; 27(2):82-9. PubMed ID: 19247976
[TBL] [Abstract][Full Text] [Related]
4. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients.
Domingo-Domènech E; Domingo-Clarós A; Gonzàlez-Barca E; Beneitez D; Alonso E; Romagosa V; De Sanjos S; Petit J; Grañena A; Fernández de Sevilla A
Haematologica; 2002 Oct; 87(10):1021-7. PubMed ID: 12368155
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience.
Gentile M; Mauro FR; Calabrese E; De Propris MS; Giammartini E; Mancini F; Milani ML; Guarini A; Foà R
Br J Haematol; 2005 Aug; 130(4):549-57. PubMed ID: 16098069
[TBL] [Abstract][Full Text] [Related]
6. Expression levels of CD38 on leukemic B cells but not on non-leukemic T cells are comparably stable over time and predict the course of disease in patients with chronic lymphocytic leukemia.
Eisele L; Haddad T; Sellmann L; Dührsen U; Dürig J
Leuk Res; 2009 Jun; 33(6):775-8. PubMed ID: 18922578
[TBL] [Abstract][Full Text] [Related]
7. ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia.
Ertault-Daneshpouy M; Noguera ME; Gisselbrecht C; Haddad A; Brice P; Marolleau JP; Soulier J; Mounier N
Clin Adv Hematol Oncol; 2008 Jan; 6(1):55-63. PubMed ID: 18322442
[TBL] [Abstract][Full Text] [Related]
8. CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: patient survival in comparison to age- and sex-matched population data.
Hock BD; McKenzie JL; McArthur L; Tansley S; Taylor KG; Fernyhough LJ
Intern Med J; 2010 Dec; 40(12):842-9. PubMed ID: 20002855
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic characterization of the leukemic B-cells from Iranian patients with chronic lymphocytic leukemia: association between CD38 expression and disease progression.
Hojjat Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Shamsian Khoramabadi A; Rabbani H; Shokri F
Iran J Immunol; 2008 Mar; 5(1):25-35. PubMed ID: 18319522
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia.
D'Arena G; Tarnani M; Rumi C; Vaisitti T; Aydin S; De Filippi R; Perrone F; Pinto A; Chiusolo P; Deaglio S; Malavasi F; Laurenti L
Am J Hematol; 2007 Sep; 82(9):787-91. PubMed ID: 17534928
[TBL] [Abstract][Full Text] [Related]
11. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia.
Hewamana S; Lin TT; Rowntree C; Karunanithi K; Pratt G; Hills R; Fegan C; Brennan P; Pepper C
J Clin Oncol; 2009 Feb; 27(5):763-9. PubMed ID: 19124804
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and outcome of Chinese patients with monoclonal B-cell lymphocytosis.
Xu W; Li JY; Wu YJ; Cao X; Fan L; Qiao C; Liu Q; Yao L; Miao KR
Leuk Res; 2009 Dec; 33(12):1619-22. PubMed ID: 19250675
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
[TBL] [Abstract][Full Text] [Related]
14. Engagement of CD31 delivers an activating signal that contributes to the survival of chronic lymphocytic leukaemia cells.
Poggi A; Prevosto C; Catellani S; Rocco I; Garuti A; Zocchi MR
Br J Haematol; 2010 Nov; 151(3):252-64. PubMed ID: 20813004
[TBL] [Abstract][Full Text] [Related]
15. Chromosome aberrations evaluated by comparative genomic hybridization in B-cell chronic lymphocytic leukemia: correlation with CD38 expression.
Ottaggio L; Viaggi S; Zunino A; Zupo S; Rossi E; Spriano M; Abbondandolo A; Ferrarini M
Haematologica; 2003 Jul; 88(7):769-77. PubMed ID: 12857555
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
17. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia.
Joshi AD; Hegde GV; Dickinson JD; Mittal AK; Lynch JC; Eudy JD; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5295-304. PubMed ID: 17875758
[TBL] [Abstract][Full Text] [Related]
18. Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination.
Rutella S; Rumi C; Puggioni P; Barberi T; Di Mario A; Larocca LM; Leone G
Haematologica; 1999 May; 84(5):419-24. PubMed ID: 10329920
[TBL] [Abstract][Full Text] [Related]
19. High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease.
Wolowiec D; Wojtowicz M; Ciszak L; Kosmaczewska A; Frydecka I; Potoczek S; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
Eur J Haematol; 2009 Apr; 82(4):260-6. PubMed ID: 19187271
[TBL] [Abstract][Full Text] [Related]
20. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
